William Tap is a Hematologist Oncology expert in New York, New York. Tap has been practicing medicine for over 23 years and is rated as an Elite expert by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. He is also highly rated in 35 other conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Angiosarcoma, Synovial Sarcoma, Tissue Biopsy, and Liver Embolization. He is licensed to treat patients in California and New York. Tap is currently accepting new patients.
Angela Hirbe is an Oncologist in Saint Louis, Missouri. Hirbe has been practicing medicine for over 14 years and is rated as an Elite expert by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. She is also highly rated in 26 other conditions, according to our data. Her top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Adult Soft Tissue Sarcoma, and Neurofibromatosis. She is licensed to treat patients in Missouri. Hirbe is currently accepting new patients.
Brian Van Tine is an Oncologist in Saint Louis, Missouri. Van Tine has been practicing medicine for over 18 years and is rated as an Elite expert by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. He is also highly rated in 38 other conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Liposarcoma, Epithelioid Sarcoma, and Vertebroplasty. He is licensed to treat patients in Missouri. Van Tine is currently accepting new patients.
Summary: This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need ...
Summary: This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib. The primary objective is to determine if there is an adequate level of disease responsiveness to binimetinib in children and adults with NF1 and inoperable plexiform neurofibromas. The objective respo...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center